Clinical trial NCT05699889: Acute Kidney Dysfunction in COVID-19 and Non-COVID-19 Related ARDS
Official title: Prevalence of COVID-19-associated Kidney Injury in ICU and Prognosis of Proximal Tubular Injury in ARDS: the URICOV Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19 Acute Respiratory Distress Syndrome
Acute Kidney Injury Due to COVID-19
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2023-01-26
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients in intensive care for SARS-CoV 2 infection with severe respiratory impairment and Patients in intensive care without SARS-CoV 2 infection with severe respiratory impairment

Brief summary: In addition to respiratory involvement, SARS-CoV 2, the virus responsible for coronavirus 2019 or Covid-19, appears to be responsible for renal involvement such as acute renal failure or proteinuria, so the mechanisms are not known at this time. The consequences of Covid-19 on renal function in the short and long term are not known.

It is important to be able to better document these renal impairments to understand the mechanisms of this disease.

The main objective of this study is to describe the prevalence of Covid-19-related renal damage (acute renal failure, proteinuria, microalbuminuria, hematuria) in a large cohort of patients in intensive care for SARS-CoV 2 infection with severe respiratory impairment.

The other objectives will be to evaluate in this cohort the impact of these renal impairments on the severity of the Covid-19 disease, and to compare them to the renal impairments of patients in intensive care for acute respiratory distress syndrome (ARDS) due to other respiratory diseases.

Blood and urine samples will be taken at the time of intubation in all critically ill patients with respiratory distress requiring mechanical ventilation for Covid-19 or other cause of respiratory distress with PaO2/FiO2 ratio \< 300.

Patients will be followed for the duration of their ICU and hospital stay. Data will be collected prospectively in three ICUs in the University Hospitals of Marseille.


Eligibility criteria: Inclusion Criteria:

* • Displaying acute respiratory distress Needing invasive mechanical ventilation

  * With PaO2/FiO2 ratio \< 300 after orotracheal intubation

Exclusion Criteria:

* Patients in ICU following thoracic surgery or lung transplantation
* Patients with cardiogenic pulmonary oedema
* Patients with end stage kidney disease
* Moribund patients

Primary outcomes:
measure: Evaluation of the incidence of acute kidney injury and tubular dysfunction
timeFrame: First 24 hours after orotracheal intubation
Secondary outcomes:
Other outcomes:
Locations:
city: Marseille
country: France
facility: Assistance Publique Hopitaux de Marseille
Study officials:
affiliation: Assistance Publique Hopitaux De Marseille
name: Emilie GARRIDO-PRADALIE
role: STUDY_DIRECTOR
affiliation: Assistance Publique Hopitaux De Marseille
name: Mickaël BOBOT
role: PRINCIPAL_INVESTIGATOR
References: